Post by icemandios on Apr 18, 2023 12:39:10 GMT
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations
“Xeris’ strategy is to patent early and often, including through a castle/moat approach that has led to numerous filings both at the platform and product levels. The addition of this new patent further strengthens our intellectual property position in the XeriSol™ platform portion of our portfolio and has claims that will cover the Gvoke formulation, which is in all our currently marketed Gvoke products,” said Paul R. Edick, Xeris’ Chairman and CEO.
The Xeris patent portfolio consists of 178 total patents globally, of which 33 are U.S. issued; 128 patent applications pending globally, of which 21 are pending in the U.S.; and 60 patents pertaining to its technology platform. Xeris’ XeriSol patent portfolio includes patents and applications directed to this platform formulation technology, commercial and pipeline pharmaceutical product formulations, and therapeutic methods using such formulations to treat a variety of human diseases and disorders. All patents are owned by Xeris Biopharma subsidiaries.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris has a diverse pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect™ to support long-term product development and commercial success.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com , or follow us on Twitter , LinkedIn or Instagram .